Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc. engages in the development of innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its products portfolio consists of cell therapy technology, CD38-GEAR-NK, and an in vitro diagnostic, CD38-Diagnostic, targeting CD38-related cancer. The company is headquartered in Wexford, PA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa. , Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa. , Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages.

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

513(g) request will help initiate dialogue with FDA and guide regulatory pathway WEXFORD, Pa. , Aug. 1, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has submitted a 513(g) request to the U.S. Food and Drug Administration (FDA) for an in vitro companion diagnostic test designed to be used with anti-CD38 monoclonal antibody therapies.

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

WEXFORD, Pa. , June 16, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the closing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses.

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

WEXFORD, Pa. , June 14, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses.

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Trading to commence effective with the open of business on June 13, 2023 WEXFORD, Pa. , June 9, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today that it received approval from the Nasdaq Stock Market of the Company's request to transfer its listing to the Nasdaq Capital Market from the Nasdaq Global Select Market.

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa. , May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately.

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

SNAP-CAR represents a major advance potentially expanding the targeting capabilities of chimeric antigen receptor (CAR) T cells for various cancers and other indications WEXFORD, Pa. , May 10, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that research involving its SNAP-CAR technology was detailed in a peer-reviewed article published in the peer-reviewed journal, Nature Communications.

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. ("Deverra Therapeutics") pursuant to which it has obtained an exclusive right, until August 31, 2023, to negotiate towards the acquisition or license of assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. Deverra Therapeutics is currently advancing clinical programs investigating these technologies in relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with respiratory viral infections.

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Potential acquisition of VyGen-Bio would strengthen Coeptis' oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies WEXFORD, Pa. , March 29, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets.

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies

Coeptis Therapeutics (NASDAQ: COEP ) stock is climbing higher on Monday despite a lack of news from the drug company. Investors searching for the reason why COEP stock is up today won't find much news.

Why Is Coeptis Therapeutics (COEP) Stock Up 14% Today?

SNAP-CAR recognized in research detailing advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility WEXFORD, Pa. , March 21, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that its SNAP-CAR technology was highlighted in a peer-reviewed article published in the Journal of Translational Medicine.

Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine

Coeptis strengthens measures to protect shareholder interests through ShareIntel's investigation and due diligence services WEXFORD, Pa. , Feb. 7, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced the Company has retained Shareholder Intelligence Services, LLC ("ShareIntel") for a 12-month, full-service agreement to review the trading patterns of the Company's common stock; monitor, identify and reconcile discrepancies; and target illegal short selling activities.

Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling

IQVIA Hlds

Coeptis to collaborate with IQVIA, a global contract research organization, to identify target indications and initiate IND-enabling activities for SNAP-CAR WEXFORD, Pa. , Nov. 22, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)  ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced an agreement with IQVIA, a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, to support the development of SNAP-CAR, a multi-antigen chimeric antigen receptor T cell (CAR T) technology that Coeptis licensed from the University of Pittsburgh.

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

WEXFORD, Pa. , Nov. 15, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that President, Chairman and CEO Dave Mehalick and other members of the management team will ring the Nasdaq Opening Bell on Wednesday, Nov. 16, 2022.

Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell

WEXFORD, Pa. , Nov. 8, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that two members of its Scientific Advisory Board, Hans-Gustaf Ljunggren, M.D.

Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast

New directors join Coeptis' Board following completion of merger with Bull Horn Holdings and advancement to Nasdaq WEXFORD, Pa. , Nov. 2, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the appointment of new directors to the Company's  board of directors (the "Board") following the completion of the previously announced business combination between Coeptis Therapeutics, Inc. and the Company and initiation of trading of the Company's common stock and public warrants under the trading symbols COEP and COEPW on the Nasdaq Global Market.

Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments

Bull Horn Holdings Corp.

Many sponsors face challenges as they race the clock to find a target amid regulatory crackdown and waning enthusiasm.

This SPAC is merging with an already-public company as sponsors get creative before time runs out

Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa. , May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors.

Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

Coeptis Therapeutics Inc (OTC: COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ: STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5) agonist platform, including entolimod.  Coeptis will agree to pay.

Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform

Statera Biopharma Inc

Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD, Pa. , April 13, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that the Company has entered into a strategic agreement with Statera Biopharma, Inc. (Nasdaq: STAB) that gives Coeptis the right to acquire Statera's toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome.

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma

WEXFORD, Pa., Jan. 20, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formation of its Scientific Advisory Board (SAB), which will contribute key guidance on the advancement of the Company's product portfolio highlighted by CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic, which the company is co-developing with VyGen-Bio, Inc.  The Scientific Advisory Board is comprised initially of three renowned scientific researchers from the Karolinska Institutet, Stockholm, Sweden; Evren Alici, M.D.

News for Coeptis Therapeutics Holdings, Inc. Stock (COEP)